A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Trial details
- Registry ID
- NCT07065240
- Drugs studied
- SPT-300
TrialRedline tracks 2 clinical trials sponsored by Seaport Therapeutics: 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 | SPT-300 | Recruiting | 2027-03Estimated |
| An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700 | SPT-300 | Enrolling by invitation | 2027-05Estimated |
Names as written in the registry records.